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 Objective: The objective of this study was to evaluate the trend of HPV vaccine 
initiation and completion among girls in Texas from 2008 to 2010. 
Methods: Data were obtained from the Behavioral Risk Factors Surveillance 
System (BRFSS) over 3 years (2008–2010). The information regarding HPV vaccination 
was gathered from the parents of 9- to 17-year-old daughters (choosing only 1 per 
household) in randomly selected households in the sample area. 
Results: The highest prevalence of vaccine initiation and completion were detected 
in 2010 (20.9% and 9.7%, respectively). Over the study period, HPV vaccine initiation 
statistically significantly increased (2008, 14.9%; 2009, 20.7%; 2010, 24.3%; p = 
0.002), corresponding to an annual increase in coverage of 33.5% (odds ratio [OR] = 
1.33; 95% confidence interval [CI]: 1.11–1.60). Similarly, HPV vaccination completion 
increased (2008, 6.3%; 2009, 9.6%; 2010, 11.6%; p = 0.021), corresponding to an 
annual increase in coverage of 37.1% (OR = 1.37; 95% CI: 1.05–1.79). Increasing trends 
in HPV vaccination initiation and completion were observed in mothers, white, non-
Hispanic parents, parents who had attended some college or were college graduates, 
parents who were married/partnered, and parents who lived in urban areas. 
Conclusion: Although HPV vaccination coverage in Texas is lower than 
recommended, there have been increases in the trends of vaccine initiation and 
completion. The campaigns promoting HPV vaccination should target specific 
population groups in which HPV immunization rates did not increase over time. 
[P R Health Sci J 2017;36:152-158]
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In 2007 the Advisory Committee on Immunization Practices (ACIP) recommended routinely administering a quadrivalent HPV vaccine to females aged 9 to 26 years, with 
females aged 11 to 12 comprising the target (with associated age 
range) for the vaccination (1, 2). In the United States (US), the 
cost of HPV vaccination is covered by health insurance as well 
as the federal Vaccines for Children program (3). Additionally, 
numerous states have introduced legislation to require the 
HPV vaccine, fund the vaccine, or educate the public about 
the vaccine (4).
Previous analyses of the data from the Behavioral Risk Factor 
Surveillance System (BRFSS) highlighted variations in the 
coverage of the HPV vaccine in girls aged 14 to 17 across 6 states 
(5). Pruitt et al.’s study indicated that the lowest rate (20.6%) 
of HPV vaccination (≥1 vaccine injection) was reported in 
Texas, while the highest (50.4%) was observed in New York 
(5). Despite an attempt to make HPV vaccination mandatory 
in Texas in 2007 (6), the rate of vaccine coverage remained 
the lowest of the states surveyed in the following year (5). 
Furthermore, cancer registry data suggested that most counties 
in Texas had low compliance of cervical cancer screening 
among adult women, while the incidence and mortality of that 
particular cancer in the state remained high (7). Thus, low 
vaccine coverage in this population could lead to the persistence 
of cancer burden associated with HPV infection in the following 
decades (8).
Although a recent rise in the rate of HPV vaccination has been 
observed at the national level, the coverage in Texas remains one 
of the lowest in the country (9). Given that HPV is the most 
common sexually transmitted disease (10) and is the principal 
risk factor for the development of cervical cancer later in life 
(11), there is an increasing concern that full HPV vaccination 
coverage of girls aged 13 to 15 will not reach the US Department 
of Health and Human Services Healthy People 2020 goal of 
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80% by 2020 (12). Furthermore, the President’s Cancer Panel 
(12) considers the increasing of HPV vaccination rates to be a 
national priority: Current disparities in vaccination uptake could 
(probably will) later lead to like disparities in cervical cancer 
incidence. For this reason, in order to increase HPV vaccination 
uptake, the panel has suggested, then, that reducing the number 
of missed opportunities for recommending or administering 
(or both) the vaccine to eligible adolescents would result in 
increasing the uptake of the vaccination, as would maximizing 
the acceptance of the vaccine by parents and caregivers and 
overall access to it (12). 
Because of the continuously low proportion of females who 
are being immunized against the HPV infection in Texas, it is 
necessary to identify whether there is a change in the trajectory 
of HPV vaccine coverage; particular attention must be paid to 
the disparities experienced by certain population subgroups 
The aim of the BRFSS survey was to evaluate the trends of HPV 
vaccine initiation and completion among adolescent females in 
Texas from 2008 to 2010 and to describe potential disparities 
in HPV vaccination among girls in the population of that state.
Materials and Methods
Behavioral risk factor surveillance system
The Centers for Disease Control and Prevention’s BRFSS is a 
state-based telephone interview survey conducted each year to 
monitor the health-related behaviors, chronic health conditions, 
and use of preventive services of US citizens aged 18 and above 
(13). State-level sampling and weighting was used to obtain a 
representative sample (in each state) of the general population 
living in households with land telephones. Post-stratification, 
the method of choice for weighting data in the BRFSS, 
consisted of simultaneously adjusting for age, race/ethnicity, 
sex, geographic region, and other characteristics to those 
proportions identified in the US Census (14). As of 2006, a more 
sophisticated weighting method was used; it included iterative 
proportional fitting, which allowed researchers to adjust for 
each variable individually in a series of data processing–intensive 
iterations. Finally, the weights were adjusted until the sample 
weights were deemed representative of the population (14). 
The BRFSS survey consists of core modules, optional modules, 
and state-added questions. The child HPV-vaccination module 
is optional and is not used assessed in all states. Furthermore, 
this module was not used in BRFSS surveys after 2010.
Data collection
Data on child HPV vaccination were available for 3 
consecutive years (2008, 2009, 2010). Because of changes in 
the data collection (the inclusion of households with cellular 
telephones, only), including analyses that cross over from 2010 
to 2011 is not recommended as such analyses have the potential 
to influence the validity of survey results (14). The dataset for 
our survey included residents of Texas, exclusively. The choice to 
include only the members of that population in our sample was 
made based on the availability of said residents as well as their 
having already been surveyed using the “child HPV vaccination” 
optional module for several consecutive years. The information 
regarding HPV vaccination was gathered from the parents of 
randomly selected children, aged 9 to 17 years. The analyses 
included girls, only, because data regarding boys were collected 
only for 2010. The HPV vaccination status was evaluated by 
asking “Has this child ever had an HPV vaccination?” followed 
by “How many HPV shots did she receive?” Parents who 
responded affirmatively to the former question were considered 
to have initiated the HPV vaccination. Other variables in the 
analysis were race/ethnicity (non-Hispanic white, non-Hispanic 
black, Hispanic, and other), level of education (high school or 
less/some college or more), income of parents (<$50,000 vs. ≥ 
$50,000 annual income), and the geographic area in which the 
household was located (urban, suburban, rural). Information 
regarding whether the responding parent had undergone a 
routine check-up in the year prior to the survey (yes, no) was 
also taken into consideration.
The Institutional Review Board (IRB) of the City College 
of New York considered the ethical aspects of this research 
and determined that this analysis did not qualify as “human 
subject research” as defined by federal regulations (45 CFR 
46.102(d) (f)). Therefore, no further IRB review or approval 
was required.
Statistical analysis
Summary statistics describing the study sample included 
proportions. Vaccination coverage according to selected 
categories was presented as percentages, with corresponding 
95% confidence intervals (CI). All estimates were adjusted for 
unequal probability sampling weight and post-stratification. 
When calculating 95% CIs and p-values, we adjusted for the 
multistage sampling design of the BRFSS survey. Linear trend 
was analyzed for HPV vaccine initiation (first dose) and for HPV 
vaccination completion (all 3 doses received). In the equation 
estimating linear trend, the dependent variables were HPV 
coverage rates for each of the 3 years, according to parental socio-
demographic characteristics, while the independent variable was 
time (2008–2010). Odds ratios (OR) and corresponding 95% 
CIs were calculated to assess the increase in trend per year. A 
probability level of p less than 0.05 was considered statistically 
significant. The statistical analysis was performed using the SAS 
software package, version 9.3.
Results
For the period of 2008 to 2010, there were a total of 3,085 
parents whose children were eligible for HPV vaccination. The 
socio-demographic characteristics of these parents are shown in 
Table 1. Most respondents were non-Hispanic whites (48.3%), 
had attended some college or were college graduates (59.1%), 
were married (70.8%) and had 1 child in their household 
(42.2%), had a household income of $50,000 or more (51.7%), 
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and lived in urban areas (58.8%). More than one half (59.4%) 
of the parents had had a routine check-up in the year prior to 
the survey.
Table 2 displays the prevalences of HPV shots according 
to parental socio-demographic characteristics. The highest 
prevalence of vaccine initiation and completion were detected 
in 2010. Overall, the highest vaccination coverage in all the 
examined categories was noted for 1 HPV shot. On the other 
hand, the lowest prevalence was observed for vaccination 
completion (all 3 HPV shots).
Over the study period, HPV initiation statistically significantly 
increased (2008, 14.9%; 2009, 20.7%; 2010, 24.3%; p = 0.002) 
(Table 3), corresponding to an annual increase in coverage of 
33.5% (OR = 1.33; 95% CI: 1.11–1.60). A statistically significant 
increasing trend in the rates of HPV initiation was observed in 
mothers (p = 0.008; 30% increase/year), white, non-Hispanic 
parents (p<0.001; 60% increase/year), parents who had 
attended some college or were college graduates (p<0.001; 54% 
increase/year), parents who were married/partnered (p<0.001; 
50% increase/year), parents who had 2 children in their 
household (p = 0.021; 48% increase/year), parents 
who lived in urban areas (p = 0.018; 33% increase/
year), and parents who had had a routine check-up in 
the year prior to the survey (p<0.001; 80% increase/
year) (Table 3). We observed this trend in families 
with annual incomes of both less than $50,000 and 
$50,000 and higher (Table 3). By 2010, the highest 
initiation rate was 37%, and most subgroups had 
initiation rates ranging from 20% to 28%.
Similar to what we noted regarding vaccine 
initiation, we observed an overall increase in 
the tendency to complete the process of HPV 
vaccination (2008, 6.3%; 2009, 9.6%; 2010, 11.6%; p 
= 0.021) (Table 3). The estimated annual increase in 
coverage of all 3 doses of HPV vaccine (vaccination 
completion) was 37.1% (OR = 1.37; 95% CI: 
1.05–1.79). A statistically significant increase in the 
trend of HPV completion was registered in mothers 
(p = 0.008; 39% increase/year), white, non-Hispanic 
parents (p = 0.001; 71% increase/year), parents who 
had attended some college or were college graduates 
(p = 0.009; 50% increase/year), parents who were 
either married/partnered or divorced (p = 0.001; 
61% increase/year and p = 0.040, 50% increase/
year, respectively), parents who had 1 child in their 
household (p = 0.025; 50% increase/year), parents 
who lived in urban areas (p = 0.019; 51% increase/
year), and parents who had not reported having had 
a routine check-up in the year prior to the survey (p = 
0.017; 64% increase/year) (Table 4). Similar to what 
was noted in vaccine initiation, the increasing trend 
in HPV vaccine completion was observed in families 
with annual incomes of both less than $50,000 and 
$50,000 and higher (Table 4). By 2010, the highest 
completion rate was 24.0%, and most subgroups had completion 
rates that ranged from 10% to 15%.
Discussion
Since 2010 the BRFSS survey has not included a module 
for collecting HPV vaccination data for children (13). For this 
reason, the trend analysis presented in this research article 
provides important findings. The results of our study show 
that HPV vaccination initiation and completion in adolescent 
girls in Texas increased from 2008 to 2010 in many population 
subgroups. This means that in spite of this state’s having one 
of the lowest state coverage rates (5, 9), an overall increasing 
(over time) tendency in responding to HPV vaccination is 
present. Similarly, in North Carolina, an upward trend was 
observed among adolescent girls for the same period (15). 
However, compared with girls in North Carolina (15), girls 
in Texas had roughly 2 times lower rates of overall vaccine 
initiation (40–50% in North Carolina versus 20–28% in 
Texas) in 2010.
Table 1. Socio-demographic characteristics of parents of children eligible to be 
vaccinated for HPV who participated in the 2008–2010 BRFSS survey in Texas
                                  Year   
Variable 2008 2009 2010 Overall
 n (%) n (%) n (%) 
Totals 791 (100.0) 833 (100.0) 1461 (100.0) 3085 (100.0)
Sex
   Female 555 (70.1) 531 (63.7) 973 (66.6) 2059 (66.7)
   Male 236 (29.9) 302 (36.3) 488 (33.4) 1026 (33.3)
Race/Ethnicity
   Non-Hispanic white 418 (52.8) 439 (52.7) 632 (43.3) 1489 (48.3)
   Non-Hispanic black 64 (8.1) 70 (8.4) 99 (6.8) 233 (7.5)
   Hispanic 280 (35.4) 284 (34.1) 680 (46.5) 1244 (40.3)
   Other 29 (3.7) 40 (4.8) 50 (3.4) 119 (3.9)
Education 
   High school or less 313 (39.6) 302 (36.2) 648 (44.3) 1263 (40.9)
   Some college or more 478 (60.4) 531 (63.8) 813 (55.7) 1822 (59.1)
Marital status
   Married/partnered 546 (69.0) 596 (71.6) 1041 (71.2) 2183 (70.8)
   Divorced 144 (18.2) 132 (15.8) 236 (16.2) 512 (16.6)
   Other 101 (12.8) 105 (12.6) 184 (12.6) 390 (12.6)
Number of children 
in household
   1 363 (45.9) 345 (41.4) 594 (40.7) 1302 (42.2)
   2 246 (31.1) 305 (36.6) 464 (31.8) 1015 (32.9)
   ≥3 182 (23.0) 183 (22.0) 403 (27.5) 768 (24.9)
Household income
   <$50,000 (US) 410 (51.8) 385 (46.2) 801 (54.8) 1596 (51.7)
   ≥$50,000 (US) 381 (48.2) 448 (53.8) 660 (45.2) 1489 (48.3)
MSA code
   Urban 419 (53.0) 512 (61.5) 882 (60.4) 1813 (58.8)
   Suburban 246 (31.1) 232 (27.8) 351 (24.0) 829 (26.9)
   Rural 126 (15.9) 89 (10.7) 228 (15.6) 443 (14.4)
Routine check-up 
in past year
   Yes 497 (62.8) 498 (59.8) 839 (57.4) 1834 (59.4)
   No 294 (37.2) 335 (40.2) 622 (42.6) 1251 (40.6)
Legend. MSA: metropolitan statistical area
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Although an increase in vaccination trend was 
noted at the state level, vaccination initiation 
improved to a greater degree in certain population 
groups. For instance, our results show that mothers 
were more likely to report that their daughters had 
initiated and completed the vaccination process. 
Regarding vaccine initiation, a similar finding was 
described for girls in North Carolina (15). A rising 
trend of reporting HPV initiation was observed 
among male parents, which was at the level of 
marginal statistical significance. Women—both 
mothers and caregivers—might be more involved 
than their male counterparts in the health and in 
the vaccination status of the children for whom 
they are responsible. Several studies suggested that 
both mothers and fathers may inaccurately report 
vaccination uptake (16–18). In line with this, various 
authors have reported somewhat conflicting findings 
(16–18). Stupiansky et al. documented that, even 
though recall of vaccination had high sensitivity and 
reasonable specificity, only 76% of the participating 
mothers/female caregivers actually knew whether 
their daughters/wards had received the HPV vaccine 
(16). Adequate accuracy in the classification of the 
HPV vaccination status of daughters has also been 
reported by Ojha et al. (17), while a recent report 
using a smaller sample of parents (79 in total) than 
were used in the former 2 studies reported that 
40% of parents or guardians had failed to recall the 
accurate number of HPV shots that their daughters 
had received (18). Given the reports, it is reasonable 
to presume that parents/caregivers may under-report 
vaccine uptake.
In terms of race/ethnicity, a significant increase 
in HPV vaccine initiation and completion was 
observed in Texas in non-Hispanic whites. By 
contrast, non-Hispanic blacks had the highest rates of 
vaccination in 2008 and 2010, but the coverage did not improve 
with time. As a result, racial/ethnic disparities may appear to 
be lessening since some population subgroups (non-Hispanic 
blacks) will not continue to make the same gains in health 
experienced by others (non-Hispanic whites). Our results are 
also comparable to those of the US Health Information National 
Trends Survey (19). Specifically, white women were found to 
be 1.86 times more willing to vaccinate their daughters (19). In 
North Carolina, however, a statistically significant increasing 
trend of initiating HPV vaccination was seen in populations 
other than non-Hispanic whites and non-Hispanic blacks (15). 
Data from 2009 from Hispanic populations in 3 US regions, 
including Texas, indicated moderate levels of vaccine awareness 
among caregivers/parents (20). Barriers to HPV immunization 
in this population included concerns about negative effects 
on the daughter’s sexual behavior, fertility, and overall health 
(21). Although higher levels of acculturation are associated 
with a greater likelihood of vaccination in low-income Hispanic 
communities, physician recommendation and low concern 
about paying for the vaccine have been deemed as independent 
predictors of HPV vaccine uptake (22).
A significant increase in the proportion of physicians who 
always recommend HPV vaccine for female patients aged 11 or 
12 years was observed from 2009 to 2011 (22). However, this 
was not noticed for patients aged 13 to 17 years (22). In North 
Carolina, for example, an increase in vaccination initiation was 
observed among those who had a regular health care provider 
(15). According to the 2009 National Immunization Survey-
Teen, adolescents who received a recommendation from their 
health care providers were 4.81 times more likely to undergo 
HPV vaccination, regardless of race/ethnicity, compared with 
those who did not receive such a recommendation (23). Still, 
racial/ethnic minorities were less likely overall to receive this 
kind of recommendation (23). Vadaparampil et al. (24) pointed 
Table 2. Prevalence of HPV shots according to parental socio-demographic 
characteristics
                                    HPV vaccination
Variable	 ≥	1	shot	 ≥	2	shots	 All	3	shots
 % (95% CI) % (95% CI) % (95% CI)
Year
   2008 14.9 (11.2–18.6) 10.4 (6.9–13.9) 6.3 (3.4–9.2)
   2009 20.6 (16.3–24.9) 13.2 (8.8–17.5) 9.6 (6.7–12.5)
   2010 24.3 (20.1–28.4) 15.9 (11.8–20.0) 11.6 (8.5–14.7)
   Overall 20.9 (18.5–23.2) 13.7 (11.3–16.0) 9.7 (7.9–11.5)
Sex
   Female 23.9 (21.6–26.6) 17.0 (14.4–19.5) 12.2 (9.5–14.9)
   Male 15.6 (11.9–19.3) 8.6 (5.6–11.5) 5.6 (3.4–7.8)
Race/Ethnicity
   Non-Hispanic white 19.6 (16.5–22.7) 12.4 (9.8–14.9) 9.1 (6.9–11.2)
   Non-Hispanic black 27.7 (17.1–38.3) 21.6 (10.6–32.6) 17.8 (7.0–28.5)
   Hispanic 20.5 (16.8–24.2) 13.9 (10.7–17.0) 8.9 (6.3–11.4)
   Other 13.4 (3.2–23.5) 5.7 (1.9–13.3) 0.7 (0.3–1.7)
Educational attainment
   High school or less 20.3 (16.6–24.0) 14.0 (10.7–17.3) 9.1 (6.2–12.0)
   Some college or more 20.3 (17.4–23.2) 12.9 (10.5–15.2) 9.4 (7.2–11.5)
Marital status
   Married/partnered 19.4 (16.8–21.9) 12.4 (10.2–14.5) 8.7 (6.7–10.6)
   Divorced 25.9 (19.6–32.2) 20.3 (14.4–26.2) 12.9 (8.7–17.0)
   Other 21.1 (13.8–28.3) 13.3 (6.8–19.8) 10.2 (3.9–16.4)
Number of children 
in household
   1 20.1 (16.5–23.6) 13.9 (11.0–16.8) 9.2 (6.8–11.5)
   2 22.3 (18.0–26.6) 12.8 (9.3–16.3) 9.9 (6.8–13.0)
   ≥3 17.9 (14.3–21.4) 13.2 (9.1–17.3) 8.7 (5.0–12.4)
Household income
   <$50,000 (US) 20.4 (16.9–23.9) 13.5 (10.6–16.4) 8.1 (5.9–10.2)
   ≥$50,000 (US) 19.9 (16.6–23.2) 12.8 (10.1–15.5) 9.8 (7.2–12.3)
MSA code
   Urban 23.7 (20.2–27.2) 15.8 (13.0–18.5) 10.7 (8.1–13.2)
   Suburban 15.8 (12.19–19.5) 11.0 (7.9–14.1) 8.9 (6.0–11.8)
   Rural 21.2 (13.7–28.6) 11.1 (6.4–15.8) 5.0 (2.4–7.5)
Routine check-up 
in past year
   Yes 22.8 (19.3–26.3) 16.0 (13.4–18.5) 11.5 (9.3–13.6)
   No 17.1 (14.0–20.2) 9.9 (7.1–12.6) 6.5 (3.9–9.0)
Legend. CI: confidence interval; MSA: metropolitan statistical area
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out that in 2009, HPV vaccination rates in Florida were higher 
among the patients of pediatricians who had a private practice, 
practiced in a single specialty setting, and saw primarily non-
Hispanic white patients. To secure higher HPV vaccination 
coverage, it is essential to provide counseling and vaccination 
recommendations to all population groups.
Moreover, HPV immunization completion is another emerging 
issue. Although we observed an overall upward trend in vaccine 
completion, fewer parents reported having their daughter complete 
all 3 doses of HPV as opposed to 1 or 2 doses. One of the reasons 
for suboptimal coverage may be that HPV vaccination completion 
takes 3 doses (25). A randomized study by Romanowski et al. (26) 
observed that immune response to a 2-dose vaccine in girls aged 9 
to 14 years is comparable to the response to the standard 3-dose 
series in women aged 15 to 25 years up to 4 years after the first 
vaccination. This means that the use of a vaccine with fewer doses 
could improve HPV vaccination completion rates. Additionally, 
using a 2-dose HPV vaccine would cost less. For example, the 
decision regarding whether or not to undergo HPV vaccination is 
profoundly influenced by an individual’s health beliefs; however, 
there is a statistically significant decrease in acceptability as the 
cost of the vaccine increases (27).
Although cost issues represent a likely barrier to vaccination, 
we observed significant increases in the trends of both of the 
income categories included in our study. This was not the case 
in North Carolina, where an upward tendency of increased 
HPV vaccine initiation was observed only among families 
with annual incomes of $50,000 or more (15). However, as 
expected, a trend toward increased rates of immunization was 
documented among parents who had attended at least some 
college, both in Texas and in North Carolina (15). It was noted 
that in the decision-making process as to whether to vaccinate a 
daughter against HPV, 40% of the mothers in Southeast Texas 
made this decision independently, whereas 22% involved 
husbands/partners (28). Moreover, one third of the mothers 
included their daughters in decision making (28). However, 
in our study, as well as in North Carolina (15), significantly 
higher HPV vaccination uptake was established among those 
whose parents/guardians were married/partnered, which 
may be more reflective of other correlates such as higher 
socioeconomic status or social support. In terms of residence, 
in 2008 the highest HPV coverage was found in metropolitan 
counties (29). Similarly, over the following 2 years, a significant 
increase in HPV vaccination trends was observed in urban areas. 
In contrast, over the same 
period in North Carolina, 
an increasing tendency to 
initiate the vaccine process 
was noted in rural areas 
(15). This finding suggests 
that promotions of HPV 
vaccination should include 
suburban and remote areas, 
equally.
B e c au s e  t h e  B R FS S 
s u r v e y  c o l l e c t s  s e l f -
reported data, there may 
be some misclassifications 
of vaccination status which 
co u l d  have  c au sed  an 
over-/underestimation of 
the number of respondents 
w h o  ac t u a l l y  had  had 
their daughters vaccinated 
against HPV. The sample 
size of the racial/ethnic 
group classified as “Other” 
was much smaller than 
the other categories and 
might have been particularly 
heterogeneous (Asians/
American Indians/Pacific 
Is lander s) .  Therefore, 
t h e  t r e n d  a n a l y s i s  i n 
this subgroup should be 
interpreted with caution. 
Table 3. Trend of HPV vaccine initiation among girls aged 9–17 in Texas, 2008–2010 BRFSS
                          HPV vaccine initiation 
Parental	characteristics	 2008		 2009	 2010	 OR	(95%	CI)*	 Wald	χ2 p
 % (95% CI) % (95% CI) % (95% CI)   
Sex
   Female 18.7 (14.0–23.4) 23.9 (18.4–29.4) 28.1 (23.2–33.0) 1.30 (1.07–1.58) 6.94 0.008
   Male 9.5 (3.2–15.7) 17.2 (10.9–23.5) 18.8 (12.1–25.5) 1.40 (0.96–2.03) 3.09 0.079
Race/Ethnicity
   Non-Hispanic white 10.2 (6.9–13.5) 22.3 (16.8–27.8) 24.8 (18.7–30.9) 1.60 (1.27–2.00) 15.81 <0.001
   Non-Hispanic black 24.3 (3.5–45.1) 20.7 (1.8–22.5) 37.2 (20.7–53.7) 1.43 (0.69–2.95) 0.95 0.330
   Hispanic 17.8 (11.1–24.5) 20.0 (13.4–26.9) 23.2 (17.3–29.1) 1.18 (0.89–1.57) 1.36 0.244
   Other 24.1 (8.8–39.4) 16.3 (5.0–37.7) 3.3 (0.4–6.2) 0.37 (0.16–0.86) 5.34 0.020
Educational attainment
   High school or less 16.8 (9.7–23.8) 23.9 (17.2–30.5) 20.4 (14.7–26.1) 1.09 (0.82–1.45) 0.33 0.566
   Some college or more 13.7 (9.8–17.6) 18.5 (13.2–23.8) 26.9 (21.4–32.4) 1.54 (1.23–1.93) 13.82 <0.001
Marital status
   Married/partnered 10.7 (7.8–13.6) 21.7 (16.8–26.6) 23.8 (19.1–28.5) 1.50 (1.24–1.83) 17.20 <0.001
   Divorced 21.6 (9.8–33.4) 35.1 (23.1–47.1) 24.3 (16.5–32.1) 1.03 (0.71–1.50) 0.03 0.858
   Other 29.4 (13.1–45.7) 10.5 (3.2–17.7) 28.1 (15.9–40.2) 1.05 (0.60–1.85) 0.03 0.859
Number of children 
in household
   1 17.1 (11.4–22.8) 17.6 (11.7–23.5) 24.9 (18.4–31.4) 1.29 (0.98–1.70) 3.36 0.067
   2 14.9 (7.4–22.3) 22.2 (15.1–29.2) 28.3 (20.6–35.9) 1.48 (1.06–2.07) 5.30 0.021
   ≥3 10.8 (5.1–16.5) 23.2 (13.4–33.0) 18.9 (12.0–25.8) 1.25 (0.90–1.74) 1.78 0.181
Household income
   <$50,000 (US) 14.2 (9.3–9.1) 21.9 (15.0–28.8) 24.3 (18.2–30.4) 1.35 (1.05–1.75) 5.42 0.020
   ≥$50,000 (US) 12.4 (8.1–16.7) 19.5 (13.8–25.2) 25.6 (19.3–31.9) 1.53 (1.19–1.98) 10.75 0.001
MSA code
   Urban 19.1 (13.4–24.8) 21.4 (16.1–26.7) 28.8 (22.9–34.7) 1.33 (1.05–1.69) 5.63 0.018
   Suburban 12.3 (5.8–18.8) 14.1 (7.6–20.6) 19.5 (13.4–25.6) 1.33 (0.92–1.91) 2.35 0.125
   Rural 8.8 (3.5–14.1) 36.4 (20.1–52.7) 20.7 (8.3–33.0) 1.35 (0.86–2.11) 1.72 0.189
Routine check-up 
in past year
   Yes 6.7 (3.8–9.6) 18.8 (11.7–25.8) 23.1 (17.0–29.2) 1.80 (1.36–2.39) 16.86 <0.001
   No 20.4 (14.7–26.1) 22.2 (17.1–27.3) 25.1 (19.6–30.6) 1.15 (0.91–1.44) 1.39 0.239
Legend. CI: confidence interval; OR: odds ratio; MSA: metropolitan statistical area, *year effect, bold values are statistically significant
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Additionally, pediatricians may not routinely offer the vaccine to 
younger girls (9 and 10 years old), which age group we included 
in the analysis. This vaccine is proven to be safe and effective 
for girls as young as 9 but should be given before sexual debut, 
and some pediatricians might feel more comfortable bringing 
up the topic of vaccination to the parents of girls who are 11 
or 12 (or older). Therefore, it might be that the coverages of 
initiation and completion might differ according to the age of 
the child/adolescent (9- to 10-year-olds vs. 11- to 13-year-olds, 
for example).
Although HPV vaccination coverage in Texas is lower 
than is recommended, there were significant increases in 
the tendencies to initiate and complete the process of HPV 
vaccination. Because HPV vaccination has a profound role 
in improving public health, Campaigns promoting HPV 
vaccination should target specific population groups in which 
HPV immunization rates did not significantly increase over 
time. It is strongly recommended that HPV uptake surveillance 
continue among girls. Given that the HPV vaccine also is 
recommended for boys, the monitoring of HPV vaccination 
among boys is also warranted.
Resumen
Objetivo: El objetivo de 
este estudio fue evaluar la 
tendencia de la iniciación de 
la vacuna contra el VPH en 
las niñas en Texas desde 2008 
a 2010. Métodos: Los datos se 
obtuvieron del “Behavioral 
Risk Factors Surveillance 
System” (BRFSS) durante 
tres  años  (2008-2010). 
La información sobre la 
vacunación contra el VPH 
se recopiló de los padres 
de las hijas de 9 a 17 años 
(eligiendo sólo 1 por hogar) 
en los hogares seleccionados 
al azar. La información sobre 
la vacunación contra el VPH 
fue recopilada de los padres 
de una hija seleccionada 
aleatoriamente de 9 a 17 años 
en el hogar. Resultados: La 
iniciación de vacunación más 
alta, así como la prevalencia de 
la finalización de vacunación 
se detectó en 2010 (20.9% 
y 9.7% respectivamente). Se 
observó aumento del inicio 
de vacunación (2008, 14.9%; 
2009, 20.7%; 2010, 24.3%; p 
= 0.002) con un aumento de cobertura de 33.5% al año (odds 
ratio [OR] = 1.33, intervalo de confianza 95% [IC] 1.11-1.60). 
Se observó aumento de la finalización de vacunación (2008, 
6.3%; 2009, 9.6%, 2010, 11.6%; p=0.021) con un aumento 
de cobertura de 37.1% al año (OR=1.37, 95% IC 1.05-1.79). 
Ambos aumentos se observaron entre madres, los padres 
blancos que no eran hispanos, los que asistieron a universidad 
o eran graduados universitarios, los padres que eran casados/
en una relación, y vivían en zonas urbanas. Conclusión: A pesar 
de que la cobertura de vacunación contra el VPH en Texas es 
más baja de la recomendada, hay aumentos en la tendencia de 
la iniciación y finalización de vacunación. La promoción de la 
vacunación debe dirigirse a grupos específicos de población en 
la que la inmunización contra el VPH no aumentó con el tiempo.
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